November 11, 2016 / 6:16 PM / 3 years ago

BRIEF-Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study

Nov 11 (Reuters) - Adaptimmune Therapeutics Plc :

* Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study at the 2016 annual meeting of the Connective Tissue Oncology Society (CTOS)

* median survival for Cohort 1 now calculated to be about 18 months (80 weeks) versus about 13 months (56 weeks) as previously reported

* other updates indicate there continue to be additional partial responses among low NY-ESO expressors in Cohort 2, that is ongoing Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below